Abstract: Combined combustion and pyrolysis (CCP) systems, and associated systems and methods, are disclosed herein. In some embodiments, the CCP system includes an input valve fluidly coupleable to a fuel supply to receive a hydrocarbon reactant, a CCP reactor fluidly coupled to the input valve, and a carbon separation component fluidly coupled to the CCP reactor. The CCP reactor can include a combustion chamber, a reaction chamber in thermal communication with the combustion chamber and/or fluidly coupled to the input valve, and an insulating material positioned to reduce heat loss from the combustion chamber and/or the reaction chamber. The CCP reactor can also include a combustion component positioned to combust a fuel within the combustion chamber. The combustion can heat the reaction chamber and the hydrocarbon reactant flowing therethrough. The heat causes a pyrolysis of the hydrocarbon reactant that generates hydrogen gas and carbon.

Abstract: Systems for producing hydrogen gas for local distribution, consumption, and/or storage, and related devices and methods are disclosed herein. A representative system includes a pyrolysis reactor system that can be coupled to a supply of reaction material that includes a hydrocarbon. The pyrolysis reactor system includes one or more combustion components positioned to transfer heat to the reaction material to convert the hydrocarbon into an output that includes hydrogen gas and carbon particulates. The pyrolysis reactor system also includes a carbon separation system positioned to separate the hydrogen gas the carbon particulates in the output. In various embodiments, the system also includes components to locally consume the filtered hydrogen gas, such as a power generator, heating appliance, and/or a combined heat and power device.

Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

Abstract: Combined combustion and pyrolysis (CCP) systems, and associated systems and methods, are disclosed herein. In some embodiments, the CCP system includes an input valve fluidly coupleable to a fuel supply to receive a hydrocarbon reactant, a CCP reactor fluidly coupled to the input valve, and a carbon separation component fluidly coupled to the CCP reactor. The CCP reactor can include a combustion chamber, a reaction chamber in thermal communication with the combustion chamber and/or fluidly coupled to the input valve, and an insulating material positioned to reduce heat loss from the combustion chamber and/or the reaction chamber. The CCP reactor can also include a combustion component positioned to combust a fuel within the combustion chamber. The combustion can heat the reaction chamber and the hydrocarbon reactant flowing therethrough. The heat causes a pyrolysis of the hydrocarbon reactant that generates hydrogen gas and carbon.

Abstract: Systems for producing hydrogen gas for local distribution, consumption, and/or storage, and related devices and methods are disclosed herein. A representative system includes a pyrolysis reactor system that can be coupled to a supply of reaction material that includes a hydrocarbon. The pyrolysis reactor system includes one or more combustion components positioned to transfer heat to the reaction material to convert the hydrocarbon into an output that includes hydrogen gas and carbon particulates. The pyrolysis reactor system also includes a carbon separation system positioned to separate the hydrogen gas the carbon particulates in the output. In various embodiments, the system also includes components to locally consume the filtered hydrogen gas, such as a power generator, heating appliance, and/or a combined heat and power device.

Abstract: The disclosure provides a method of treating or preventing overactive bladder syndrome (OBS) in a human subject (with normal renal function, mild renal impairment, or mild to moderate renal impairment) in need of such treatment, comprising administering to the human subject a therapeutically effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof. In one embodiment, the method comprises administering the compound of formula (IA).

Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

Abstract: The invention provides an oral dosage form comprising (i) an amount of oxycodone and (ii) an amount of buprenorphine, wherein the weight ratio of the amount of buprenorphine to the amount of oxycodone is greater than 1:40 calculated with the amount of buprenorphine in the dosage form expressed as the equimolar amount of buprenorphine base (Mw=467.64 g/mol) in mg, and the amount of oxycodone in the dosage form expressed as the equimolar amount of oxycodone hydrochloride (Mw=351.82 g/mol) in mg. The invention also provides combinations of an opioid agonist and buprenorphine for use to treat pain, wherein the combination achieves a reduction of adverse pharmacodynamic responses (such as, respiratory depression), compared with a corresponding stand-alone opioid therapy. The invention also includes methods of treatment and dosage forms thereof comprising such combinations.

Abstract: The invention relates to a solid dosage form comprising a core-shell structure comprising two or more different active agents, wherein the core-shell structure comprises (1) a core comprising a first matrix formulation, the first matrix formulation comprising at least one active agent selected from the group of an active agent (A) and an active agent (B); and (2) a shell encasing the core and comprising a second matrix formulation, wherein the weight ratio of the first matrix formulation to the second matrix formulation is from about 1:10 to about 4:1. In certain embodiments, the solid dosage forms of the invention are in oral solid extended release dosage forms, which provide an extended release of at least a portion of at least one active agent included therein.

Abstract: The invention provides an oral dosage form comprising (i) an amount of oxycodone and (ii) an amount of buprenorphine, wherein the weight ratio of the amount of buprenorphine to the amount of oxycodone is greater than 1:40 calculated with the amount of buprenorphine in the dosage form expressed as the equimolar amount of buprenorphine base (Mw=467.64 g/mol) in mg, and the amount of oxycodone in the dosage form expressed as the equimolar amount of oxycodone hydrochloride (Mw=351.82 g/mol) in mg. The invention also provides combinations of an opioid agonist and buprenorphine for use to treat pain, wherein the combination achieves a reduction of adverse pharmacodynamic responses (such as, respiratory depression), compared with a corresponding stand-alone opioid therapy. The invention also includes methods of treatment and dosage forms thereof comprising such combinations.

Abstract: A technology is described for a wide-band radio frequency amplifier using cross-over diplexers. A first port is configured to receive RF signals in a wide-band RF spectrum. A cross-over diplexer splitter is coupled to the first port. The cross-over diplexer splitter is configured to filter the RF signals in the wide-band RF spectrum into a low frequency (LF) signal having an LF pass-band and a high frequency (HF) signal having an HF pass-band with the LF pass-band crossing the HF pass-band at a cross-over frequency. An HF RF amplifier is configured to amplify the HF signal to form an amplified HF signal. An LF RF amplifier configured to amplify the LF signal to form an amplified LF signal. A cross-over diplexer combiner is configured to combine the amplified HF signal and the amplified LF signal and output amplified RF signals in the wide-band RF spectrum.

Abstract: The disclosure provides a method of treating interstitial cystitis/bladder pain syndrome in a human subject in need of such treatment, comprising administering to the human subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In certain embodiments, the method comprises administering the compound of formula (IA).

Abstract: The invention relates to a solid dosage form comprising a core-shell structure comprising two or more different active agents, wherein the core-shell structure comprises (1) a core comprising a first matrix formulation, the first matrix formulation comprising at least one active agent selected from the group of an active agent (A) and an active agent (B); and (2) a shell encasing the core and comprising a second matrix formulation, wherein the weight ratio of the first matrix formulation to the second matrix formulation is from about 1:10 to about 4:1. In certain embodiments, the solid dosage forms of the invention are in oral solid extended release dosage forms, which provide an extended release of at least a portion of at least one active agent included therein.

Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

Abstract: A turbine shroud assembly for a gas turbine engine includes a shroud wall extending circumferentially partway around a central reference axis to define a gas path of the gas turbine engine. An attachment feature extends radially from the shroud wall. A foam is located at least on the shroud wall.

Abstract: A system and method for recommending demand-supply agent pairs for transactions uses a deep neural network on data of demand agents to produce a demand agent vector, which is used to select supply agents based on their likelihood of future transaction and to find k nearest neighbor demand agents for each of the demand agents. The candidate supply agents and the k nearest neighbor demand agents are then combined to produce candidate demand-supply agent pairs, which are used to find recommended demand-supply agent pairs by applying modeling using machine learning.

Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

Abstract: A turbine vane assembly adapted for use in a gas turbine engine includes a support and a turbine vane arranged around the support. The support is made of metallic materials. The turbine vane is made of ceramic matrix composite materials to insulate the metallic materials of the support.

Abstract: A method of altering a surface of a ceramic matrix composite to aid in nodule removal is described. A fiber preform comprising a framework of ceramic fibers is heated to a temperature at or above a melting temperature of silicon. During the heating, the fiber preform is infiltrated with a molten material comprising silicon. After the infiltration, the fiber preform is cooled, and the infiltrated fiber preform is exposed to a gas comprising nitrogen during cooling. Silicon nitride may be formed by a reaction of free (unreacted) silicon at or near the surface of the infiltrated fiber preform with the nitrogen. Thus, a ceramic matrix composite having a surface configured for easy nodule removal is formed. Any silicon nodules formed on the surface during cooling may be removed without machining or heat treatment.

Abstract: An airfoil assembly for a gas turbine engine includes an airfoil extending radially relative to a central reference axis. A spar is located within the airfoil and spaced from the airfoil at all radial locations along the airfoil such that a gap is maintained between the airfoil and the spar. A foam is located between the airfoil and the spar.